

Edgar Filing: Norwegian Cruise Line Holdings Ltd. - Form SC 13G

Norwegian Cruise Line Holdings Ltd.  
Form SC 13G  
February 13, 2017

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No. )\*

Norwegian Cruise Line Holdings Ltd.  
(Name of Issuer)

Ordinary Shares  
(Title of Class of Securities)

B9CGTC3  
(CUSIP Number)

December 30, 2016  
(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- Rule 13d-1(b)  
 Rule 13d-1(c)  
 Rule 13d-1(d)

\*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Edgar Filing: Norwegian Cruise Line Holdings Ltd. - Form SC 13G

CUSIP: B9CGTC3

Page 1 of 5

- 1 NAMES OF REPORTING PERSONS  
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)  
Capital International Investors \*\*
- 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a)
- 3 SEC USE ONLY (b)
- 4 CITIZENSHIP OR PLACE OF ORGANIZATION  
California
- 5 SOLE VOTING POWER  
12,206,806
- 6 SHARED VOTING POWER  
NONE
- 7 SOLE DISPOSITIVE POWER  
12,904,558
- 8 SHARED DISPOSITIVE POWER  
NONE
- 9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
12,904,558 Beneficial ownership disclaimed pursuant to Rule 13d-4
- 10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
- 11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9  
5.6%
- 12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)  
IA

\*\* A division of Capital Research and Management Company (CRMC)

Edgar Filing: Norwegian Cruise Line Holdings Ltd. - Form SC 13G

CUSIP: B9CGTC3

Page 2 of 5

SECURITIES AND EXCHANGE COMMISSION  
Washington, DC 20549

Schedule 13G  
Under the Securities Exchange Act of 1934

Amendment No.

- Item 1(a) Name of Issuer:  
Norwegian Cruise Line Holdings Ltd.
- Item 1(b) Address of Issuer's Principal Executive Offices:  
7665 Corporate Drive  
Miami, FL 33126
- Item 2(a) Name of Person(s) Filing:  
Capital International Investors, division of Capital Research  
and Management Company
- Item 2(b) Address of Principal Business Office or, if none,  
Residence:  
11100 Santa Monica Boulevard  
16th Floor  
Los Angeles, CA 90025
- Item 2(c) Citizenship: N/A
- Item 2(d) Title of Class of Securities:  
Ordinary Shares
- Item 2(e) CUSIP Number:  
B9CGTC3
- Item 3 If this statement is filed pursuant to sections 240.13d-1(b)  
or 240.13d-2(b) or (c), check whether the person filing is a:  
(e)  An investment adviser in accordance with  
section 240.13d-1(b) (1) (ii) (E).
- Item 4 Ownership

Provide the following information regarding the aggregate  
number and percentage of the class of securities of the issuer  
identified in Item 1.

- (a) Amount beneficially owned:  
(b) Percent of class:  
(c) Number of shares as to which the person has:  
(i) Sole power to vote or to direct the vote:  
(ii) Shared power to vote or to direct the vote:  
(iii) Sole power to dispose or to direct the disposition of:  
(iv) Shared power to dispose or to direct the disposition of:

See page 2

Edgar Filing: Norwegian Cruise Line Holdings Ltd. - Form SC 13G

Capital International Investors division of Capital Research and Management Company ("CRMC") and the following CRMC subsidiaries: Capital Guardian Trust Company, Capital International Limited, Capital International Sarl, Capital International K.K. and Capital International, Inc.,

CUSIP: B9CGTC3

Page 3 of 5

collectively provide investment management services under the name "Capital International Investors." Please see Items 5 through 11 of each reporting person's cover sheet in this Schedule 13G filing for such person's deemed beneficial ownership of 12,904,558 shares or 5.6% of the 227,179,962 shares believed to be outstanding.

Item 5 Ownership of Five Percent or Less of a Class. If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: [ ]

Item 6 Ownership of More than Five Percent on Behalf of Another Person: N/A

Item 7 Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person: N/A

Item 8 Identification and Classification of Members of the Group: N/A

Item 9 Notice of Dissolution of Group: N/A

Item 10 Certification

By signing below, I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

Signature

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: February 8, 2017

Signature: \*\*Robert W. Lovelace  
Name/Title: Robert W. Lovelace, Partner  
Capital International Investors

\*\*\*By /s/ Walter R. Burkley  
Walter R. Burkley

## Edgar Filing: Norwegian Cruise Line Holdings Ltd. - Form SC 13G

Attorney-in-fact

Signed pursuant to a Power of Attorney dated January 4, 2017 included as an Exhibit to Schedule 13G filed with the Securities and Exchange Commission by Capital International Investors on January 10, 2017 with respect to Agios Pharmaceuticals, Inc.

CUSIP: B9CGTC3

Page 4 of 5

CUSIP: B9CGTC3

Page 5 of 5